Ms. Johnson is the interim Chief Business Officer at Riva Therapeutics and brings over 30 years experience in drug development, licensing, strategy, and corporate development. She is also the Chief Business Officer of Reneo Pharmaceuticals, where she served as Reneo’s Chief Development Officer and was the company’s founding Chief Operating Officer. She currently serves on the Board of Directors of Exagen, Inc. and was previously on the Board of Directors of MorphoSys AG and AmpliPhi Biosciences (merged to form Armata Pharmaceuticals). She served on the investment team at ProQuest Investments and was the president and CEO of Aires Pharmaceuticals (acquired by Mast Therapeutics). She also served as Senior Vice President of corporate development, at Salmedix Inc. (acquired by Cephalon/Teva), and held executive roles at WomenFirst Healthcare, Selective Genetics and Cytel. Earlier in her career, she was assistant director with the Center for Devices and Radiological Health at the U.S. Food and Drug Administration.
Ms. Johnson holds an M.B.A. from Loyola University, an M.S. in clinical microbiology from the Hahnemann Medical School and a B.S. in microbiology from the University of Maryland.